P Debijelaan 25

Dr. P Debijelaan 25

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
TAThomas van Amelsfort
Thomas van Amelsfort
VWValentijn S.C. Webers
Valentijn S.C. Webers
P2P Debijelaan 25
P Debijelaan 25
LCLaurentius H.H. Clement
Laurentius H.H. Clement
FBFrank J.H.M. van Den Biggelaar
Frank J.H.M. van Den Biggelaar
RNRudy M.M.A. Nuijts
Rudy M.M.A. Nuijts
PURPOSE: Evaluating visual outcomes, spectacle independence, and optical phenomena after bilateral implantation of a non-diffractive extended depth-of-focus (EDOF) IOL targeted for mini-monovision. SETTING: University Eye Clinic Maastricht, the Netherlands. DESIGN: Prospective case series. METHODS: Patients with age-related cataract were bilaterally implanted with a non-diffractive EDOF IOL (Alcon Acrysof IQ Vivity), targeted for mini-monovision. Outcome measures were the uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), distance corrected intermediate visual acuity (DCIVA), distance corrected near visual acuity (DCNVA), refractive outcomes, defocus-curves, spectacle independence, photic phenomena and Catquest-9SF questionnaires. RESULTS: 44 eyes of 22 patients were included. Binocular UDVA, UIVA and UNVA were -0.07 (± 0.10), 0.04 (± 0.09) and 0.23 (± 0.12) logMAR, respectively. The percentage of eyes within 1.0D and 0.5D of target was 100% and 95% for the dominant eye, 100% and 86% for the nondominant eye. The binocular defocus-curve was better than 0.10 logMAR over a range from -2.0D to +0.5D. The percentage of patients who reported no or rarely using glasses for distance, intermediate and near viewing distance was 96%, 68%, 38%, respectively. The percentage of patients who experienced no halos, glare or starbursts were 91%, 91%, 100%, respectively. Catquest-9SF showed a high patient satisfaction for daily life activities. CONCLUSION: Bilateral Acrysof IQ Vivity IOL implantation targeted for mini-monovision, provides good visual acuity results for far and intermediate with functional near vision, high level of patient satisfaction and spectacle independence, and a monofocal disturbance profile.

10 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CBCarlien Bennebroek
Carlien Bennebroek
JZJudith van Zwol
Judith van Zwol
GPGiorgio L. Porro
Giorgio L. Porro
OOOostenbrink Oostenbrink
Oostenbrink Oostenbrink
ADAnne Dittrich
Anne Dittrich
AMAntoinette Y. N. Schouten-van Meeteren
Antoinette Y. N. Schouten-van Meeteren
Backgrounds: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide studies are lacking. Methods: We performed a retrospective, nationwide, multicentre cohort study including all pediatric patients with OPG treated with BVZ in the Netherlands (2009–2021). Progression-free survival, change in visual acuity and visual field, MRI-based radiologic response, and toxicity were evaluated. Results: In total, 33 pediatric patients with OPG were treated with BVZ (median 12 months). Visual acuity improved in 20.5%, remained stable in 74.4%, and decreased in 5.1% of 39 of all analysed eyes. The monocular visual field improved in 73.1%, remained stable in 15.4%, and decreased in 7.7% of 25 analysed eyes. Radiologic response at the end of therapy showed a partial response in 7 patients (21.9%), minor response in 7 (21.9%), stable disease in 15 (46.9%), and progressive disease in 3 (9.3%). Progression-free survival at 18 and 36 months after the start of BVZ reduced from 70.9% to 38.0%. Toxicity (≥grade 3 CTCAE) during treatment was observed in five patients (15.2%). Conclusion: Treatment of BVZ in pediatric patients with OPG revealed stabilisation in the majority of patients, but was followed by progression at a later time point in more than 60% of patients. This profile seems relatively acceptable given the benefits of visual field improvement in more than 70% of analysed eyes and visual acuity improvement in more than 20% of eyes at the cessation of BVZ.

1 April 2021 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
MTMariel W.A. Teunissen
Mariel W.A. Teunissen
EKErik-Jan Kamsteeg
Erik-Jan Kamsteeg
SSSuzanne C.E.H. Sallevelt
Suzanne C.E.H. Sallevelt
MPMaartje Pennings
Maartje Pennings
P2P Debijelaan 25
P Debijelaan 25
JNJoost Nicolai
Joost Nicolai
Objective We describe a third patient with brain small vessel disease 3 (BSVD3), being the first with a homozygous essential splice site variant in the COLGALT1 gene, with a more severe phenotype than the 2 children reported earlier. Methods Analysis of whole exome sequencing (WES) data of the child and parents was performed. We validated the missplicing of the homozygous variant using reverse transcription PCR and Sanger sequencing of the mRNA in a lymphocyte culture. Results The patient presented antenatally with porencephaly on ultrasound and MRI. Postnatally, he showed a severe developmental delay, refractory epilepsy, spastic quadriplegia, and a progressive hydrocephalus. WES revealed a homozygous canonical splice site variant NM_024656.3:c.625-2A>C. PCR and Sanger sequencing of the mRNA demonstrated that 2 cryptic splice sites are activated, causing a frameshift in the major transcript and in-frame deletion in a minor transcript. Conclusions We report a third patient with biallelic pathogenic variants in COLGALT1, confirming the role of this gene in autosomal recessive BSVD3.

25 January 2023 in JMIR Formative Research
Verified
Journal Article
Open access
JCJanneau Claessens
Janneau Claessens
JEJuultje van Egmond
Juultje van Egmond
JWJoukje Wanten
Joukje Wanten
P2P Debijelaan 25
P Debijelaan 25
RNRudy Nuijts
Rudy Nuijts
RWRobert Wisse
Robert Wisse
Background: Telehealth solutions can play an important role in increasing access to eye care. Web-based eye tests can enable individuals to self-assess their visual function remotely without the assistance of an eye care professional. A web-based tool for self-assessing visual acuity (VA) has previously been studied in controlled, supervised conditions. The accuracy of this tool when performed independently by patients in their home environment, using their own devices, has not yet been examined. Objective: The objective of this paper was to examine the accuracy of a web-based tool with respect to measuring VA in ophthalmic patients in their home environment, compared with a conventional in-hospital assessment using a Snellen chart (the gold standard). Methods: From April through September 2020, consecutive adult patients with uveitis at the University Medical Center Utrecht, the Netherlands, performed the web-based VA test at home (the index test) before their upcoming conventional VA assessment at the hospital (the reference test). The agreement between the 2 tests was assessed by the Bland-Altman analysis. Additional analyses were performed to investigate associations between clinical characteristics and the accuracy of the web-based test. Results: A total of 98 eyes in 59 patients were included in the study. The difference in VA between the index and reference tests was not significant, with a mean difference of 0.02 (SD 0.12) logMAR (P=.09) and 95% limits of agreement of –0.21 to 0.26 logMAR. The majority of the differences (77%) fell within the predetermined acceptable deviation limit of 0.15 logMAR. In addition, no patient characteristics or clinical parameters were found to significantly affect the accuracy of the web-based test. Conclusions: This web-based test for measuring VA is a valid tool for remotely assessing VA, also when performed independently by patients at home. Implementation of validated web-based tools like this in the health care system may represent a valuable step forward in revolutionizing teleconsultations and can provide individual patients with the opportunity to self-monitor changes in VA. This is particularly relevant when the patient’s access to ophthalmic care is limited. Future developments should focus on optimizing the testing conditions at home to reduce outliers.

1 May 2025 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Open access
JWJoukje C. Wanten
Joukje C. Wanten
P2P Debijelaan 25
P Debijelaan 25
TBTos TJM Berendschot
Tos TJM Berendschot
FBFrank Van Den Biggelaar
Frank Van Den Biggelaar
RNRudy M.M.A. Nuijts
Rudy M.M.A. Nuijts
Purpose: To evaluate the symptoms, etiology, and treatment of patient dissatisfaction after extended depth-of-focus (EDOF) intraocular lens (IOL) implantation. Setting: University Eye Clinic, Maastricht University Medical Center, the Netherlands. Design: Retrospective case series. Methods: For this study, all medical records of patients who received an EDOF IOL from July 2020 to July 2022 were reviewed. Patients were included if they had reported any dissatisfaction after surgery. The main outcome parameters were reasons for dissatisfaction (subjective complaints) and the presumed etiology of the complaints. Results: Of 202 patients (354 eyes) who underwent EDOF IOL implantation, 83 eyes (22.8%) of 52 dissatisfied patients were included. Blurred vision was the predominant complaint, reported in 78 eyes (94%). Photic phenomena were reported in 21 eyes (25.3%), with 16 eyes (76.2%) experiencing coexisting blurred vision. The major etiologies for dissatisfaction in this cohort were residual ametropia (51.8%), dry eye disease (26.5%), and posterior capsular opacification (12.0%). Treatments were administered to 85.5% of the eyes, including interventions such as artificial tears, spectacles, or refractive surgery enhancement. A small number of patients (n = 12; 5.9%) remained dissatisfied despite intervention. Conclusions: Based on this real-world data study, dissatisfaction after EDOF IOL implantation can be effectively identified and treated in most cases.

19 August 2021 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Open access
LSLindsay S. Spekreijse
Lindsay S. Spekreijse
P2P Debijelaan 25
P Debijelaan 25
FBFrank Van Den Biggelaar
Frank Van Den Biggelaar
RSRob W.P. Simons
Rob W.P. Simons
CVClaudette A. Veldhuizen
Claudette A. Veldhuizen
RNRudy M.M.A. Nuijts
Rudy M.M.A. Nuijts
Purpose: To evaluate refractive outcomes for the Clareon monofocal intraocular lens (IOL) in terms of achieved target refraction for the ORA (ALCON) intraoperative wavefront aberrometry device and preoperative noncontact biometry. Setting: University Eye Clinic Maastricht, Maastricht University Medical Center+, the Netherlands. Design: Prospective observational clinical trial. Methods: Patients with bilateral age-related cataracts undergoing phacoemulsification, either by delayed sequential surgery or on the same day, were included in the study. Exclusion criteria were an increased risk for refractive surprise or complicated surgery. Implanted IOL power was based on noncontact optical biometry data using the Barrett Universal II (BU-II) formula, optimized for the Clareon IOL. Postoperative subjective refraction was measured 4 to 6 weeks after surgery. Catquest-9SF questionnaires were completed preoperatively and 3 months after surgery. Results: 100 eyes (51 patients) were included. The percentages of eyes within 1.0 diopters (D), 0.75 D, 0.50 D, and 0.25 D of target for ORA vs BU-II were 84% (84 eyes), 72% (72 eyes), 57% (57 eyes), and 21% (21 eyes) vs 97% (97 eyes), 88% (88 eyes), 77% (77 eyes), and 53% (53 eyes), respectively. Mean absolute prediction error was significantly higher for ORA vs preoperative biometry (P < .001). After global optimization, the prediction accuracy of ORA improved significantly (P < .001). Catquest-9SF questionnaires showed improved levels of ability at 3 months after surgery (P < .001). Conclusions: This study showed lower percentages of eyes within target refraction for ORA (prior to lens constant optimization) compared with the BU-II formula when implanting the Clareon IOL. However, prediction accuracy of ORA improved significantly after global optimization. Therefore, further intraoperative measurements, postoperative measurements, and optimization are needed to improve the ORA prediction for this IOL.